PARP10-IN-3

Cat. No.:	HY-148754
CAS No.:	2225800-19-9
Molecular Formula:	$C_{14}H_{12}N_2O_3$
Molecular Weight:	256.26
Target:	PARP
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (195.11 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.9023 mL	19.5114 mL	39.0229 mL
	5 mM	0.7805 mL	3.9023 mL	7.8046 mL
	10 mM	0.3902 mL	1.9511 mL	3.9023 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC_{50} of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on PARP2 and PARP15 with IC_{50}s of 1.7 μM for human PARP2 and human PARP15, respectively[1].

IC_{50} & Target

human PARP10 480 nM (IC_{50})	human PARP2 1.7 μM (IC_{50})	human PARP15 1.7 μM (IC_{50})	human TNKS2 6.5 μM (IC_{50})
human PARP4 7 μM (IC_{50})	human TNKS1 21 μM (IC_{50})	human PARP14 41 μM (IC_{50})	human PARP12 >10 μM (IC_{50})
human PARP16 >10 μM (IC_{50})	human PARP1 >100 μM (IC_{50})	human PARP3 >100 μM (IC_{50})	

In Vitro

PARP10-IN-3 (compound 20) has an IC_{50} of 1-2 μM by olony‐formation assay (CFA) in HeLa‐PARP10 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Patricia Korn, et al. Evaluation of 3- and 4-Phenoxybenzamides as Selective Inhibitors of the Mono-ADP-Ribosyltransferase PARP10. ChemistryOpen. 2021 Oct;10(10):939-948.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA